Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: water for injections; disodium edetate; sodium hydroxide - as an antidote for paracetamol poisoning: acetylcysteine injection concentrate is indicated in the treatment of paracetamol overdose to protect against hepatotoxicity.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium acetate trihydrate; glacial acetic acid - levetiracetam sandoz concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.,levetiracetam sandoz concentrate solution for iv infusion is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with jme. ? add on therapy in the treatment of pgtc seizures in adults and children from 4 years of age with ige.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer and breast cancer, after failure of standard therapy. treatment of non-small cell lung cancer (nsclc). adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their previous metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dexmedetomidine hydrochloride, quantity: 236 microgram (equivalent: dexmedetomidine, qty 200 microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - icu sedation,for sedation of initially intubated patients during treatment in an intensive care setting.,the use of dexmedetomidine by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dexmedetomidine hydrochloride, quantity: 118 microgram/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride - icu sedation,for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine sandoz by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid - cabazitaxel juno in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.